Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 2OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 1

Interventions

pembrolizumab 604Carboplatin 374Paclitaxel 283Cisplatin 270Gemcitabine 252Pemetrexed 194Bevacizumab 191Docetaxel 186Nivolumab 180Injections 169Cyclophosphamide 150atezolizumab 139Fluorouracil 134Capecitabine 133Oxaliplatin 132Dexamethasone 128durvalumab 113Fulvestrant 113130-nm albumin-bound paclitaxel 110fludarabine 103Cetuximab 100Leucovorin 97Rituximab 95venetoclax 90Lenalidomide 83enzalutamide 77Prednisone 77Azacitidine 74Irinotecan 73Doxorubicin 72

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × ixabepilone × 1 year × Clear all
NCT04796324 2026-03-12

Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.

Allarity Therapeutics

Phase 2 Terminated
13 enrolled 8 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡